Evidence map›Paper›PMID 31875196›Full record

ArticleJournal of the American Academy of Orthopaedic Surgeons. Global research & reviews2019

Relationship Between Pain Alleviation and Disease-specific Health-related Quality of Life Measures in Patients With Chronic Low Back Pain Receiving Duloxetine: Exploratory Post Hoc Analysis of a Japanese Phase 3 Randomized Study.

Hiroyuki Enomoto, Nao Sasaki, Shinji Fujikoshi, Aki Yoshikawa, Toshinaga Tsuji, Katsushi Takeshita

Registry-linked trialAbstract read
In one paragraph

Article in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01855919 (Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Low Back Pain in Japan), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01855919 phase3completednot on this map

Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Low Back Pain in Japan

TypeinterventionalSponsorEli Lilly and CompanyRan2013 to 2014Enrolled458ConditionsBack Pain Lower Back ChronicArmsDuloxetine, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hiroyuki EnomotoMedicines Development Unit Japan, Eli Lilly Japan K.K., Akasaka, Minato-Ku, Tokyo, Japan (Dr. Enomoto); the Medicines Development Unit Japan, Eli Lilly Japan K.K., Chuo-Ku, Kobe, Japan (Ms. Sasaki, Mr. Fujikoshi, and Ms. Yoshikawa); the Medical Affairs Department, Shionogi & Co., Ltd., Kita-ku, Osaka, Japan (Dr. Tsuji); and the Department of Orthopaedic Surgery, Jichi Medical University, Tochigi, Japan (Dr. Takeshita).
Nao SasakiMedicines Development Unit Japan, Eli Lilly Japan K.K., Akasaka, Minato-Ku, Tokyo, Japan (Dr. Enomoto); the Medicines Development Unit Japan, Eli Lilly Japan K.K., Chuo-Ku, Kobe, Japan (Ms. Sasaki, Mr. Fujikoshi, and Ms. Yoshikawa); the Medical Affairs Department, Shionogi & Co., Ltd., Kita-ku, Osaka, Japan (Dr. Tsuji); and the Department of Orthopaedic Surgery, Jichi Medical University, Tochigi, Japan (Dr. Takeshita).
Shinji FujikoshiMedicines Development Unit Japan, Eli Lilly Japan K.K., Akasaka, Minato-Ku, Tokyo, Japan (Dr. Enomoto); the Medicines Development Unit Japan, Eli Lilly Japan K.K., Chuo-Ku, Kobe, Japan (Ms. Sasaki, Mr. Fujikoshi, and Ms. Yoshikawa); the Medical Affairs Department, Shionogi & Co., Ltd., Kita-ku, Osaka, Japan (Dr. Tsuji); and the Department of Orthopaedic Surgery, Jichi Medical University, Tochigi, Japan (Dr. Takeshita).
Aki YoshikawaMedicines Development Unit Japan, Eli Lilly Japan K.K., Akasaka, Minato-Ku, Tokyo, Japan (Dr. Enomoto); the Medicines Development Unit Japan, Eli Lilly Japan K.K., Chuo-Ku, Kobe, Japan (Ms. Sasaki, Mr. Fujikoshi, and Ms. Yoshikawa); the Medical Affairs Department, Shionogi & Co., Ltd., Kita-ku, Osaka, Japan (Dr. Tsuji); and the Department of Orthopaedic Surgery, Jichi Medical University, Tochigi, Japan (Dr. Takeshita).
Toshinaga TsujiMedicines Development Unit Japan, Eli Lilly Japan K.K., Akasaka, Minato-Ku, Tokyo, Japan (Dr. Enomoto); the Medicines Development Unit Japan, Eli Lilly Japan K.K., Chuo-Ku, Kobe, Japan (Ms. Sasaki, Mr. Fujikoshi, and Ms. Yoshikawa); the Medical Affairs Department, Shionogi & Co., Ltd., Kita-ku, Osaka, Japan (Dr. Tsuji); and the Department of Orthopaedic Surgery, Jichi Medical University, Tochigi, Japan (Dr. Takeshita).
Katsushi TakeshitaMedicines Development Unit Japan, Eli Lilly Japan K.K., Akasaka, Minato-Ku, Tokyo, Japan (Dr. Enomoto); the Medicines Development Unit Japan, Eli Lilly Japan K.K., Chuo-Ku, Kobe, Japan (Ms. Sasaki, Mr. Fujikoshi, and Ms. Yoshikawa); the Medical Affairs Department, Shionogi & Co., Ltd., Kita-ku, Osaka, Japan (Dr. Tsuji); and the Department of Orthopaedic Surgery, Jichi Medical University, Tochigi, Japan (Dr. Takeshita).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This post hoc analysis of a Japanese phase 3 randomized study (ClinicalTrials.gov identifier: NCT01855919) investigated relationships between pain severity (assessed by the Brief Pain Inventory [BPI]) and disease-specific health-related quality of life (assessed by the 24-item Roland-Morris Disability Questionnaire [RDQ-24]) in duloxetine-treated patients with chronic low back pain (CLBP).

methodsPatients with CLBP duration >6 months and BPI average score ≥4 received duloxetine 60 mg/d (N = 230) or placebo (N = 226) for 14 weeks. Spearman rank correlation coefficients were calculated for (1) BPI change from baseline and RDQ item change from baseline and (2) BPI change from baseline and the RDQ item baseline score in duloxetine-treated patients.

resultsDuloxetine treatment significantly improved the RDQ-24 total score compared with placebo; the greatest improvements were observed for RDQ02, RDQ17, and RDQ13. The strongest correlations between BPI change from baseline and RDQ item change from baseline were for RDQ13, RDQ23, and RDQ10. The correlation coefficients for the correlations between BPI change from baseline and the RDQ item baseline score were generally small. DISCUSSION: This post hoc analysis suggested that improvement in pain severity was associated with improvement in the RDQ-24 total score and in some individual RDQ items in duloxetine-treated patients with CLBP. Furthermore, positive responses to duloxetine in terms of the RDQ13, RDQ23, and RDQ10 items may correlate with better pain responses. CLINICAL TRIAL REGISTRY: The study described in this manuscript was registered at www.clinicaltrials.gov (NCT01855919).

Identifiers

PMID31875196
PMCPMC6903819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.